BeiGene leaps as Brukinsa bests Imbruvica in Phase III CLL trial

13 October 2022

Sino-American biotech BeiGene (HKEX: 06160) shot up on Wednesday, after the company's chronic lymphocytic leukemia (CLL) treatment was shown to beat out a blockbuster drug from Johnson & Johnson (NYSE: JNJ).

BeiGene announced that its Brukinsa (zanubrutinib) achieved superior Progression-Free Survival (PFS) versus J&J’s Imbruvica (ibrutinib) in a final analysis of the Phase III ALPINE trial, as assessed by an independent review committee (IRC) and investigator. Brukinsa was generally well tolerated; safety findings at the final PFS analysis were consistent with prior reports.

American-traded shares of BeiGene closed up 20.5% at $151.67 on Wednesday, while in Hongkong they rose 13.9% to 95.99 renminbi by early afternoon trading today.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK